Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA.
2014-2-20; doi: 10.1016/j.ygyno.2014.09.021
Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3.
We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested.
We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients.
Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.
Copyright © 2014. Published by Elsevier Inc.
PMID:25284038
